DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer

Phase 2

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Liver Cancer

Interventions: Drug: dolastatin 10

First Posted Date: 2004-07-22

Last Posted Date: 2014-03-06

Lead Sponsor: University of Chicago

Target Recruit Count: 16

Registration Number: NCT00003557

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸
Michiana Hematology/Oncology P.C., South Bend, Indiana, United States

and more 8 locations

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Phase 1

Completed

Conditions: Bladder Cancer
Cervical Cancer
Endometrial Cancer
Vaginal Cancer

Interventions: Drug: paclitaxel
Drug: vinorelbine tartrate
Radiation: radiation therapy

First Posted Date: 2004-06-16

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 33

Registration Number: NCT00002949

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

Phase 2

Withdrawn

Conditions: Ovarian Cancer

Interventions: Drug: depsipeptide

First Posted Date: 2004-06-11

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Registration Number: NCT00085527

Locations: 🇺🇸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States

Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Biological: oblimersen sodium
Drug: paclitaxel

First Posted Date: 2004-06-04

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT00005032

Locations: 🇺🇸
Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 8 locations

Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: oxaliplatin
Drug: paclitaxel

First Posted Date: 2004-05-21

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 38

Registration Number: NCT00004126

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 8 locations

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: irinotecan hydrochloride
Drug: paclitaxel

First Posted Date: 2004-04-29

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 21

Registration Number: NCT00002939

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: cyclosporine
Drug: CPT-11

First Posted Date: 2004-04-27

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 16

Registration Number: NCT00003950

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 7 locations

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: bryostatin 1
Drug: paclitaxel

First Posted Date: 2004-04-26

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT00005849

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Michiana Hematology/Oncology P.C., South Bend, Indiana, United States

and more 7 locations

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: MART-1 antigen
Biological: recombinant MAGE-3.1 antigen
Biological: recombinant interleukin-12

First Posted Date: 2004-04-22

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT00002952

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: O6-benzylguanine
Drug: carmustine

First Posted Date: 2004-04-12

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT00005066

Locations: 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Division of Hematology/Oncology, Park Ridge, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy